Positron Emission Tomography-Based Response to Target and Immunotherapies in Oncology

被引：11
作者：
Donegani, Maria Isabella [1 ,2 ]
Ferrarazzo, Giulia [1 ,2 ]
Marra, Stefano [1 ,2 ]
Miceli, Alberto [1 ,2 ]
Raffa, Stefano [1 ,2 ]
Bauckneht, Matteo [1 ,2 ]
Morbelli, Silvia [1 ,2 ]
机构：
[1] Univ Genoa, Nucl Med Unit, Dept Hlth Sci, I-16132 Genoa, Italy
[2] IRCCS Osped Policlin San Martino, I-16132 Genoa, Italy
来源：
MEDICINA-LITHUANIA | 2020年 / 56卷 / 08期
关键词：
positron emission tomography; target therapy; immunotherapy; response assessment; PERCIST criteria; RESISTANT PROSTATE-CANCER; METABOLIC TUMOR VOLUME; CELL LUNG-CANCER; F-18-FDG PET/CT; FDG-PET; EARLY PREDICTION; EVALUATION CRITERIA; HODGKINS LYMPHOMA; IN-VIVO; MELANOMA;
D O I：
10.3390/medicina56080373
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2-deoxy-2-[F-18]fluoro-D-glucose ([F-18]FDG) is a promising tool to support the evaluation of response to either target therapies or immunotherapy with immune checkpoint inhibitors both in clinical trials and, in selected patients, at the single patient's level. The present review aims to discuss available evidence related to the use of [F-18]FDG PET (Positron Emission Tomography) to evaluate the response to target therapies and immune checkpoint inhibitors. Criteria proposed for the standardization of the definition of the PET-based response and complementary value with respect to morphological imaging are commented on. The use of PET-based assessment of the response through metabolic pathways other than glucose metabolism is also relevant in the framework of personalized cancer treatment. A brief discussion of the preliminary evidence for the use of non-FDG PET tracers in the evaluation of the response to new therapies is also provided.
引用
收藏
页码：1 / 22
页数：23
相关论文
共 96 条
  • [1] FDG PET/CT for assessing tumour response to immunotherapy: Report on the EANM symposium on immune modulation and recent review of the literature
    Aide, Nicolas
    Hicks, Rodney J.
    Le Tourneau, Christophe
    Lheureux, Stephanie
    Fanti, Stefano
    Lopci, Egesta
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (01) : 238 - 250
  • [2] Prediction of response to immune checkpoint inhibitor therapy using 18F-FDG PET/CT in patients with melanoma
    Amrane, Karim
    Le Goupil, Delphine
    Quere, Gilles
    Delcroix, Olivier
    Gouva, Sylvie
    Schick, Ulrike
    Salaun, Pierre-Yves
    Abgral, Ronan
    Alavi, Zarrin
    Keromnes, Nathalie
    Querellou, Solene
    [J]. MEDICINE, 2019, 98 (29) : e16417
  • [3] Comparison of 18F-FDG PET/CT Criteria for the Prediction of Therapy Response and Clinical Outcome in Patients With Metastatic Melanoma Treated With Ipilimumab and PD-1 Inhibitors
    Annovazzi, Alessio
    Vari, Sabrina
    Giannarelli, Diana
    Pasqualoni, Rosella
    Sciuto, Rosa
    Carpano, Silvia
    Cognetti, Francesco
    Ferraresi, Virginia
    [J]. CLINICAL NUCLEAR MEDICINE, 2020, 45 (03) : 187 - 194
  • [4] Is 18F-FDG PET/CT Useful for the Early Prediction of Histopathologic Response to Neoadjuvant Erlotinib in Patients with Non-Small Cell Lung Cancer?
    Aukema, Tjeerd S.
    Kappers, Ingrid
    Olmos, Renato A. Valdes
    Codrington, Henk E.
    van Tinteren, Harm
    van Pel, Renee
    Klomp, Houke M.
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2010, 51 (09) : 1344 - 1348
  • [5] Objective response rate assessment in oncology: Current situation and future expectations
    Aykan, Nuri Faruk
    Ozatli, Tahsin
    [J]. WORLD JOURNAL OF CLINICAL ONCOLOGY, 2020, 11 (02): : 53 - 73
  • [6] Ball MW, 2016, DISCOV MED, V21, P305
  • [7] Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group
    Barrington, Sally F.
    Mikhaeel, N. George
    Kostakoglu, Lale
    Meignan, Michel
    Hutchings, Martin
    Mueeller, Stefan P.
    Schwartz, Lawrence H.
    Zucca, Emanuele
    Fisher, Richard I.
    Trotman, Judith
    Hoekstra, Otto S.
    Hicks, Rodney J.
    O'Doherty, Michael J.
    Hustinx, Roland
    Biggi, Alberto
    Cheson, Bruce D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (27) : 3048 - +
  • [8] Patients with melanoma treated with an anti-PD-1 antibody beyond RECIST progression: a US Food and Drug Administration pooled analysis
    Beaver, Julia A.
    Hazarika, Maitreyee
    Mulkey, Flora
    Mushti, Sirisha
    Chen, Huanyu
    He, Kun
    Sridhara, Rajeshwari
    Goldberg, Kirsten B.
    Chuk, Meredith K.
    Chi, Dow-Chung
    Chang, Jennie
    Barone, Amy
    Balasubramaniam, Sanjeeve
    Blumenthal, Gideon M.
    Keegan, Patricia
    Pazdur, Richard
    Theoret, Marc R.
    [J]. LANCET ONCOLOGY, 2018, 19 (02) : 229 - 239
  • [9] Early response evaluation of neoadjuvant therapy with PET/MRI to predict resectability in patients with adenocarcinoma of the esophagogastric junction
    Belmouhand, Mohamed
    Lofgren, Johan
    Johannesen, Helle Hjorth
    Baeksgaard, Lene
    Gutte, Henrik
    Tariq, Kiran
    Achiam, Michael Patrick
    [J]. ABDOMINAL RADIOLOGY, 2019, 44 (03) : 836 - 844
  • [10] 89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer
    Bensch, Frederike
    van der Veen, Elly L.
    Lub-de Hooge, Marjolijn N.
    Jorritsma-Smit, Annelies
    Boellaard, Ronald
    Kok, Iris C.
    Oosting, Sjoukje F.
    Schroder, Carolina P.
    Hiltermann, T. Jeroen N.
    van der Wekken, Anthonie J.
    Groen, Harry J. M.
    Kwee, Thomas C.
    Elias, Sjoerd G.
    Gietema, Jourik A.
    Bohorquez, Sandra Sanabria
    de Crespigny, Alex
    Williams, Simon-Peter
    Mancao, Christoph
    Brouwers, Adrienne H.
    Fine, Bernard M.
    de Vries, Elisabeth G. E.
    [J]. NATURE MEDICINE, 2018, 24 (12) : 1852 - +
12345678910